ViaLase to present papers at ARVO

Glaucoma treatment usually means drops, a conventional laser, or surgery. The problem is that each option has tradeoffs — adherence is hard, laser effects can f(eyewire.news) wedge itself into that gap with a femtosecond laser system that makes a drainage opening without cutting into the eye. This week’s news is that the compan(eyewire.news)stion: how to make that laser approach work more reliably across different eye anatomies. (eyewire.news)calls FLIGHT — femtosecond laser, image-guided, high-precision trabeculotomy. Basically, the system targets the trabecular meshwork, the tissue where fluid often meets resistance, and creates a precise channel intended to improve aqueous humor outflow and lower intraocular pressure. The company already has CE Mark in Europe for adult primary open-angle glaucoma, but in the U.S. the device remains investigational. (vialase.com) ### Why does “incision-free” matter? Most glaucoma procedures that open the eye’s drainage pathway involve an incision and a surgical(eyewire.news) that step. That does not automatically mean better outcomes — that still has to be proved — but it does explain why the company keeps stressing safety, precision, and patient experience. In glaucoma, a less invasive pressure-lowering option could be attractive if it is durable enough. (vialase.com) ### So what are these ARVO papers about? Both posters zero in on the eye’s drainage system, especially Schlemm’s canal. One looks at modeling treatment i(vialase.com)ooks at optimizing outflow facility with the ViaLase procedure. Both are scheduled for the same ARVO poster session on Wednesday, May 6, from 2:00 PM to 3:45 PM in Denver. Eric Mikula is presenting one poster, and Fiona McDonnell is presenting the other. (eyewire.news) ### Why are multiple apertures the big idea? Because glaucoma outflow is not uniform around the eye. Some segments of the drainage pathway may work better than other(vialase.com)ly placed openings could engage more of the usable pathway. Think of it less like opening one stuck drain and more like testing several access points along the same pipe. That is the core scientific angle in these ARVO abstracts. (eyewire.news) ### Do they already have human data? Yes — but still early. In the first-in-human study, 18 eyes of 12 patients with open-angle glaucoma had (eyewire.news)a 34.6% reduction. The company also highlighted the absence of device-related serious adverse events in that study. Promising, yes. Definitive, no. The sample was small. (vialase.com) ### What has changed since then? The big shift is from pilot-style evidence toward a tougher U.S. test. In December 2025, ViaLase said it treated the first patient in an FDA-designed IDE trial — a prospective, multi(eyewire.news)or SLT, the current standard laser treatment for reducing eye pressure. That makes the ARVO posters feel less like science-fair extras and more like breadcrumbs ahead of a real commercial and regulatory push. (biospace.com) ### What sh(vialase.com)t anatomy-guided, multi-aperture treatment translates into better pressure control or more consistent results than a single treatment site. That is the practical question hiding underneath the engineering language. If the answer is yes, ViaLase could carve out a new category between office laser and incisional surgery. (eyewire.news) ### Bottom line? This is still a development-stage glaucoma technology, not a finished standard of care(biospace.com)ge anatomy of actual eyes. If that holds up in randomized data, the story gets much bigger fast. (eyewire.news)